CBAY   $32.16  -0.09% Market Closed After Close 32.17 0.03%

Cymabay Therapeutics Inc
Last Events:

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bullish recovery to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-07-30 Signal in Stochastic changed from bearish recovery to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2023-07-30 Signal in MACD changed from bearish reversal to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-07-29 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 8
Target Price Mean 30.75
Mean unverified/preliminary 30.75 / 30.75
Target Price Low / High 25.00 / 32.50
Median / STD DEV 32.50 / 3.25
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None Sell None
stoch None None None
ma20 Sell Buy ActivelyBuy
ma50 None None None
ma100 None Buy None
Candlestick PatternNov. 1, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US23257D1037
ceo Mr. Sujal A. Shah
Website https://www.cymabay.com
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.